Alector (ALEC) vs ProKidney (PROK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Alector (ALEC) has outperformed ProKidney (PROK) over the past year, gaining 88.3% versus a loss of 52.5%. Over five years, ALEC leads with a -88.3% price change compared with -89.5% for PROK. ProKidney is the larger company by market cap ($415.2 million vs $347.6 million), about 1.2 times the size.
Alector converts more of its revenue into profit, with a net margin of -679.2% versus -7725.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALEC | PROK |
|---|---|---|
| Share price | $2.34 | $1.04 |
| Market cap | $347.63M | $415.21M |
| 1-day change | +1.52% | -1.89% |
| YTD return | +49.68% | -53.57% |
| 1-year return | +88.31% | -52.51% |
| 5-year return | -88.28% | -89.49% |
| P/E ratio (TTM) | 6.31 | — |
| EPS (TTM) | $0.37 | $-0.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $21.05M | $893.00K |
| Revenue growth (YoY) | -79.07% | +1075.00% |
| Net income (latest FY) | $-142.93M | $-68.99M |
| Operating margin | -741.30% | -18477.83% |
| Net margin | -679.16% | -7725.20% |
| 52-week high | $2.84 | $2.65 |
| 52-week low | $1.09 | $0.87 |
| Distance from 52-week high | -17.78% | -60.75% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +89.29% | +525.00% |
| Average volume | 3.34M | 1.44M |
| Shares outstanding | 148.88M | 209.63M |
| Employees | 103 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALEC has outperformed PROK by 140.8 percentage points over the past year.
- Alector is more profitable, keeping -679.2 cents of every revenue dollar as net income versus -7725.2 cents for ProKidney.
- ProKidney grew revenue faster in its latest fiscal year (+1075.00% vs -79.07%).
About Alector
ALEC stock →Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 103 employees
About ProKidney
PROK stock →ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees
ALEC vs PROK FAQ
Which is bigger, Alector or ProKidney?
ProKidney (PROK) is larger, with a market capitalization of $415.21M compared with $347.63M for Alector (ALEC).
Which stock has performed better over the past year, ALEC or PROK?
ALEC returned +88.31% over the past 12 months, compared with -52.51% for PROK (price return, excluding dividends). Past performance does not predict future results.
Are Alector and ProKidney in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.